Curis Lifesciences Limited H1 FY26 Concall Decoded: Exports dreaming big, margins flexing muscles, and injectables teased like a Netflix sequel
1. Opening Hook
While most SME pharma concalls stick to safe jargon and Excel optimism, Curis Lifesciences went full startup-founder mode. From Sanand GIDC nostalgia to Nigeria dreams, management practically walked investors through their factory corridors—brick by brick.
Margins jumped faster than raw material prices fell, own-brand exports were pitched as the future goldmine, and injectables were dangled like a high-capex Bollywood blockbuster—“coming soon, but not today.” The tone? Confident. The ambition? Global. The patience required? A lot.
This wasn’t a “next quarter will be great” call. It was a “wait two years, then watch margins explode” sermon. If you like slow-burning export stories with regulatory hurdles and eventual operating leverage, keep reading. Things get more interesting once Nigeria enters the chat.
2. At a Glance
Revenue ₹50+ Cr FY25: No fireworks, but steady export-driven grind.
EBITDA margin ~21%: Raw material prices finally stopped partying.
PAT margin ~12%: Registered products doing the heavy lifting.
Exports ~64% of revenue: India manufactures, Africa consumes.
Own-brand sales <1%: Currently irrelevant, potentially explosive later.
3. Management’s Key Commentary
“We are stopping loan license and job work completely.” (Translation: Low-margin survival mode is officially over 😏)
“Contract manufacturing for merchant exports will be our focus.” (Translation: Better margins, less drama, same factories)
“Nigeria will be our first own-brand market.” (Translation: One year of paperwork before one rupee of revenue)
“Injectables are planned, but it’s too early to commit.” (Translation: ₹50–55 Cr capex, please don’t rush us 💉)
“EBITDA margin can reach 15%+ in FY27.” (Translation: Mix improvement > topline obsession)
“Brand building is the real wealth creator in pharma.” (Translation: Manufacturing pays bills, brands create valuation)
